Showing results (801-810 of 2,229) with videos related to

Sort By:
Pageof 223
Cancer Biotherapy & Radiopharmaceuticals|November 7, 2024
Validation of Radiosynthesis and First in-Human Dosimetry of 68Ga-NOTA-UBI-29-41: A Proof of Concept StudyParul Thakral, Nishant Rana, Navneet Singh, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 22, 2024
Theranostics, Advanced Cancer, and The Meaning of LifeJ Harvey Turner
Cancer Biotherapy & Radiopharmaceuticals|October 18, 2024
SERPINH1 as a Novel Biomarker for Colon Cancer Bone Metastasis with Machine Learning and Immunohistochemistry ValidationGuoping Zhao, Tianjun Song, Qingfa Qing, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 25, 2025
Nab-Paclitaxel Promotes Radiosensitization by Inducing DNA Damage and Inhibiting Macrophage M2 Polarization in CholangiocarcinomaNingyu Wang, Xiangping Mei, Yang Cao, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 19, 2024
A Comprehensive Analysis of LYAR in Colorectal Cancer: Prognostic Marker and Therapeutic TargetJia-Ying Wen, Ye-Ying Fang, Dong-Ming Li, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 2, 2024
Development in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma TreatmentYi-Tong Liu, He-Liang Wu, Yan-Dong Su, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 27, 2024
GRHPR, Targeted by miR-138-5p, Inhibits the Proliferation and Metastasis of Hepatocellular Carcinoma Through PI3K/AKT Signaling PathwayShuangshuang Yang, Yixian Liu, Bushi Zhang, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2006
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancerHilary Hardy Street, Michael L Goris, George Albert Fisher, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2006
High-level expression, one-step purification of soluble Ad5-knob protein and its activity assayJuyun Yang, Yanzhong Zhao, Ting Liu, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2006
Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivoJinpu Yu, Xiubao Ren, Shui Cao, et al.
Pageof 223